HIGHLIGHTS
- who: Wenying Shu from the Department of Pharmacy, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, China have published the research: The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma, in the Journal: (JOURNAL)
- what: The authors evaluated several MKIs with the capacity to inhibit ErbBs for their effect on the viability of UM cells. The authors assessed the involvement of EGFR and HER2 in the anti-cancer actions of afatinib in UM cells.
- how: The authors identified multi-kinase highly . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.